These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 10767997)

  • 1. [Chemoresistance in ovarian cancer. State of the art and future prospects].
    Katsaros D; Fracchioli S; Arese P; Enria R; Cassinelli P; Mingrone K; Piccinno R; Rigault de la Longrais IA; Massobrio M
    Minerva Ginecol; 1999 Dec; 51(12):483-99. PubMed ID: 10767997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors.
    L'Espérance S; Popa I; Bachvarova M; Plante M; Patten N; Wu L; Têtu B; Bachvarov D
    Int J Oncol; 2006 Jul; 29(1):5-24. PubMed ID: 16773180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical evaluation of p53 as a prognostic marker in ovarian cancer.
    Hall J; Paul J; Brown R
    Expert Rev Mol Med; 2004 May; 6(12):1-20. PubMed ID: 15147608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic approaches to overcoming chemoresistance in ovarian cancer.
    Suh DH; Kim MK; No JH; Chung HH; Song YS
    Ann N Y Acad Sci; 2011 Jul; 1229():53-60. PubMed ID: 21793839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.
    Reles A; Wen WH; Schmider A; Gee C; Runnebaum IB; Kilian U; Jones LA; El-Naggar A; Minguillon C; Schönborn I; Reich O; Kreienberg R; Lichtenegger W; Press MF
    Clin Cancer Res; 2001 Oct; 7(10):2984-97. PubMed ID: 11595686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nucleotide excision repair pathway review I: implications in ovarian cancer and platinum sensitivity.
    Saldivar JS; Wu X; Follen M; Gershenson D
    Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S56-71. PubMed ID: 17884153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer.
    Coukos G; Makrigiannakis A; Kang EH; Rubin SC; Albelda SM; Molnar-Kimber KL
    Clin Cancer Res; 2000 Aug; 6(8):3342-53. PubMed ID: 10955822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status.
    Quist SR; Wang-Gohrke S; Köhler T; Kreienberg R; Runnebaum IB
    Cancer Gene Ther; 2004 Aug; 11(8):547-54. PubMed ID: 15153938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug resistance in ovarian cancer: from the laboratory to the clinic.
    Sood AK; Buller RE
    Obstet Gynecol; 1998 Aug; 92(2):312-9. PubMed ID: 9699774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug resistance in ovarian cancer: the emerging importance of gene transcription and spatio-temporal regulation of resistance.
    Richardson A; Kaye SB
    Drug Resist Updat; 2005 Oct; 8(5):311-21. PubMed ID: 16233989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
    Laframboise S; Chapman W; McLaughlin J; Andrulis IL
    Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells.
    Puca R; Nardinocchi L; Pistritto G; D'Orazi G
    Gynecol Oncol; 2008 Jun; 109(3):403-10. PubMed ID: 18395248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and molecular differences between clear cell and papillary serous ovarian carcinoma.
    Eltabbakh GH; Mount SL; Beatty B; Simmons-Arnold L; Cooper K
    J Surg Oncol; 2006 Apr; 93(5):379-86. PubMed ID: 16550573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New players in ovarian cancer.
    Bovicelli A; D'Andrilli G; Giordano A
    J Cell Physiol; 2011 Oct; 226(10):2500-4. PubMed ID: 21302305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.
    Villedieu M; Louis MH; Dutoit S; Brotin E; Lincet H; Duigou F; Staedel C; Gauduchon P; Poulain L
    Gynecol Oncol; 2007 Apr; 105(1):31-44. PubMed ID: 17275076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells.
    Yang X; Xing H; Gao Q; Chen G; Lu Y; Wang S; Ma D
    Gynecol Oncol; 2005 May; 97(2):413-21. PubMed ID: 15863139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway.
    Yang X; Fraser M; Moll UM; Basak A; Tsang BK
    Cancer Res; 2006 Mar; 66(6):3126-36. PubMed ID: 16540663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TP53 and ovarian cancer.
    Schuijer M; Berns EM
    Hum Mutat; 2003 Mar; 21(3):285-91. PubMed ID: 12619114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survivin deregulation in beta-tubulin mutant ovarian cancer cells underlies their compromised mitotic response to taxol.
    Zhou J; O'brate A; Zelnak A; Giannakakou P
    Cancer Res; 2004 Dec; 64(23):8708-14. PubMed ID: 15574781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.